[go: up one dir, main page]

NZ516400A - Stable factor VIII compositions - Google Patents

Stable factor VIII compositions

Info

Publication number
NZ516400A
NZ516400A NZ516400A NZ51640000A NZ516400A NZ 516400 A NZ516400 A NZ 516400A NZ 516400 A NZ516400 A NZ 516400A NZ 51640000 A NZ51640000 A NZ 51640000A NZ 516400 A NZ516400 A NZ 516400A
Authority
NZ
New Zealand
Prior art keywords
factor viii
ions
stable factor
viii compositions
optionally
Prior art date
Application number
NZ516400A
Other languages
English (en)
Inventor
Marianne Mikaelsson
Helena Sandberg
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ516400(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9902685A external-priority patent/SE9902685D0/xx
Priority claimed from SE0001743A external-priority patent/SE0001743D0/xx
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NZ516400A publication Critical patent/NZ516400A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ516400A 1999-07-13 2000-07-07 Stable factor VIII compositions NZ516400A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9902685A SE9902685D0 (sv) 1999-07-13 1999-07-13 Stable protein compositions
US14682899P 1999-08-02 1999-08-02
SE0001743A SE0001743D0 (sv) 2000-05-11 2000-05-11 Stable protein compositions II
PCT/SE2000/001454 WO2001003726A1 (en) 1999-07-13 2000-07-07 Stable factor viii compositions

Publications (1)

Publication Number Publication Date
NZ516400A true NZ516400A (en) 2004-02-27

Family

ID=27354553

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ516400A NZ516400A (en) 1999-07-13 2000-07-07 Stable factor VIII compositions

Country Status (14)

Country Link
US (1) US6599724B1 (xx)
EP (1) EP1194161B1 (xx)
JP (1) JP4674021B2 (xx)
AR (1) AR024735A1 (xx)
AT (1) ATE310533T1 (xx)
AU (1) AU780415B2 (xx)
CA (1) CA2378751C (xx)
CY (1) CY1104986T1 (xx)
DE (1) DE60024268T2 (xx)
DK (1) DK1194161T3 (xx)
ES (1) ES2252028T3 (xx)
NO (1) NO330048B1 (xx)
NZ (1) NZ516400A (xx)
WO (1) WO2001003726A1 (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
WO2003055512A1 (en) * 2001-12-21 2003-07-10 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
CA2646498C (en) † 2002-12-27 2012-01-10 Japan Cash Machine Co., Ltd. Optical sensing device for detecting optical features of valuable papers
BRPI0408439A (pt) * 2003-03-18 2006-04-04 Novo Nordisk Healthcare Ag composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
MXPA05012476A (es) * 2003-05-23 2006-02-22 Novo Nordisk Healthcare Ag Estabilizacion de proteina en solucion.
US7498024B2 (en) 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
BRPI0413518A (pt) 2003-08-14 2006-10-10 Novo Nordisk Healthcare Ag composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
US20050090551A1 (en) * 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
AU2004296768B2 (en) * 2003-12-03 2010-06-24 University Of Rochester Recombinant factor VIII having increased specific activity
HUE038162T2 (hu) * 2003-12-19 2018-09-28 Novo Nordisk Healthcare Ag Stabilizált VII faktor polipeptid készítmények
US7422875B2 (en) 2004-07-20 2008-09-09 Board Of Regents Of The University Of Nebraska Compositions and methods for increasing protein production
US20090017007A1 (en) * 2005-08-26 2009-01-15 Maxygen Holdings Ltd. Liquid factor vii composition
FR2908892B1 (fr) * 2006-11-21 2009-02-20 Hyphen Biomed Soc Par Actions Procede pour le dosage chromogenique de l'activite du facteur viii:c et necessaire de dosage chromogenique de l'activite du facteur viii:c,dans les plasmas ou les fractions therapeutiques
MX2010004813A (es) * 2007-11-01 2010-10-04 Univ Rochester Factor viii recombinante que tiene estabilidad incrementada.
ES2649094T3 (es) 2007-12-27 2018-01-10 Baxalta GmbH Procedimientos de cultivo celular
WO2010054238A1 (en) 2008-11-07 2010-05-14 Baxter International Inc. Factor viii formulations
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
GB0915481D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
CA2816575C (en) 2010-11-05 2019-06-11 Baxter Healthcare S.A. A new variant of antihemophilic factor viii having increased specific activity
CN103517919B (zh) * 2011-05-13 2016-11-16 欧克塔医药公司 在重组fviii的生产中提高真核细胞生产率的方法
CN103917554B (zh) 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
WO2015149143A2 (en) * 2014-04-01 2015-10-08 Advantech Bioscience Farmacêutica Ltda. Stable factor viii formulations with low sugar-glycine
US9855319B2 (en) 2014-04-01 2018-01-02 Advantech Bioscience Farmacêutica Ltda Stabilization of factor VIII without calcium as an excipient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000210A1 (en) 1986-06-24 1988-01-14 Nordisk Gentofte A/S A process for producing a coagulation active complex of factor viii fragments
EP1652534A3 (en) 1992-10-02 2007-05-02 Genetics Institute, LLC Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
AU7254894A (en) * 1993-07-23 1995-02-20 Baxter International Inc. Activated human factor viii and method of preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
ATE356198T1 (de) * 1996-10-11 2007-03-15 Invitrogen Corp Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium

Also Published As

Publication number Publication date
DE60024268D1 (de) 2005-12-29
US6599724B1 (en) 2003-07-29
ATE310533T1 (de) 2005-12-15
AU6193300A (en) 2001-01-30
AR024735A1 (es) 2002-10-23
JP4674021B2 (ja) 2011-04-20
CA2378751C (en) 2012-11-06
DE60024268T2 (de) 2006-08-03
JP2003504345A (ja) 2003-02-04
ES2252028T3 (es) 2006-05-16
WO2001003726A1 (en) 2001-01-18
DK1194161T3 (da) 2006-02-13
NO20020120D0 (no) 2002-01-10
EP1194161B1 (en) 2005-11-23
CY1104986T1 (el) 2009-11-04
NO330048B1 (no) 2011-02-07
EP1194161A1 (en) 2002-04-10
AU780415B2 (en) 2005-03-17
NO20020120L (no) 2002-02-28
CA2378751A1 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
NZ516400A (en) Stable factor VIII compositions
EP1650307A3 (en) Methods for making recombinant proteins using apoptosis inhibitors
BR0108507A (pt) Cultivo livre de soro de células-tronco embriÈnicas de primatas
IL219969A (en) Cell culture containing recombinant cho cells expressing protein factor viii
IL148060A0 (en) Compositions and methods for improved cell culture
DE69725587D1 (de) Verwendung von wnt polypeptiden
AU2002316230A1 (en) Methods of culturing animal cells and polypeptide production in animal cells
EP0953041A4 (en) SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
EP1360314A4 (en) CHEMICALLY DEFINED MEDIUM FOR CULTIVATED MAMMALIAN CELLS
BR0015374A (pt) Diferenciação hematopoiética de troncocélulas embriÈnicas humanas
WO2003105252A3 (en) CERAMIC ANODES AND PROCESS FOR PRODUCING THE SAME
MY148759A (en) Methods to culture circovirus
CA2263725A1 (en) Immortalized cell lines for virus growth
PL376381A1 (en) Methods and media for controlling sialylation of proteins produced by mammalian cells
MXPA99007026A (es) Metodo para proliferacion y diferenciacion de celulas hematopoieticas y mesenquimatosas.
IL142094A0 (en) Methods of controlling proliferation and differentiation of stem and progenitor cells
ATE349540T1 (de) Expression der bazillus thuringiensis cry- proteine in pflanzen-plastiden
EP1137808A4 (en) METHODS OF MAKING RECOMBINANT CELLS
AU1262900A (en) Method for the production of fvii
AU2003210053A1 (en) Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
DE69631972D1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
AU1622302A (en) Preservation of cells
CA2337088A1 (en) Methods and constructs for protein expression
DE60313718D1 (de) Zusammensetzung zur Zellkultur, die Polyethylenglykol enthält

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 07 JUL 2020 BY CPA GLOBAL

Effective date: 20130531

EXPY Patent expired